Chordoma
47
8
16
21
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.1%
1 terminated out of 47 trials
95.5%
+8.9% vs benchmark
2%
1 trials in Phase 3/4
24%
5 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (47)
Clinical Genetics Branch Eligibility Screening Survey
Proton Beam Therapy for Chordoma Patients
Children and Adults With Chordoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Long-Term Longitudinal QoL in Patients Undergoing EEA
A Study of ERAS-601 in People With Chordoma
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
Nilotinib With Radiation for High Risk Chordoma
Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers